Physician profile
Mary E Davidian
NPI 1780683052
$31,821.30
in general payments reported to CMS, 2019-2025
37 companies · $2,314 in 2025
The $2,314 reported for 2025 was more than what 89% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $9,484 · 2020: $557 · 2021: $6,218 · 2022: $2,419 · 2023: $6,865 · 2024: $3,964 · 2025: $2,314.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,914 · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $4,950 · Travel and Lodging: $1,239 · Education: $39.34.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,914.19 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $4,950.00 |
| Travel and Lodging | $1,239.21 |
| Education | $39.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dompe US, INC. | $14,586.86 | 2019-2025 | Oxervate |
| Biotissue Holdings INC. | $6,969.28 | 2019-2025 | |
| Alcon Vision LLC | $1,533.45 | 2019-2025 | Rocklatan, Simbrinza, Hydrus Microstent |
| Abbvie INC. | $1,192.99 | 2022-2025 | Lumigan, Alphagan P, Vuity |
| Sun Pharmaceutical Industries INC. | $795.48 | 2019-2025 | Cequa |
| Sight Sciences, INC. | $725.76 | 2019-2025 | Omni Surgical System, Tearcare System, Sion Surgical Instrument |
| Mallinckrodt Hospital Products INC. | $631.56 | 2020-2025 | Acthar |
| Oyster Point Pharma, INC. | $550.69 | 2022-2025 | Tyrvaya, Ryzumvi, Ryzumvi |
| Bausch & Lomb Americas INC. | $480.99 | 2022-2025 | Miebo, Xiidra, Vyzulta |
| Lensar, INC. | $428.35 | 2024 | Lensar Laser System |
| Allergan, INC. | $417.16 | 2019-2022 | |
| Johnson & Johnson Surgical Vision, INC. | $416.21 | 2019-2025 | Tecnis Iol, Tecnis Iol |
| Novartis Pharmaceuticals Corporation | $389.54 | 2019-2023 | |
| Harrow Eye, LLC | $374.95 | 2024-2025 | Triesence, Iheezo, Vevye |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $307.43 | 2019-2021 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aerie Pharmaceuticals, INC. | $293.41 | 2019-2021 | |
| Kala Pharmaceuticals, INC. | $279.62 | 2019-2022 | |
| Tarsus Pharmaceuticals, INC. | $244.14 | 2024-2025 | Xdemvy |
| Eyepoint US, INC. | $181.35 | 2019-2020 | |
| Horizon Therapeutics Plc | $156.90 | 2021-2023 | Tepezza |
| New World Medical,INC. | $111.55 | 2021 | |
| Rayner Intraocular Lenses Limited | $98.99 | 2024-2025 | Omidria, Rayone Aspheric, Rayone Emv |
| Eyevance Pharmaceuticals LLC | $96.87 | 2020-2021 | |
| Rxsight INC | $95.38 | 2021-2025 | Rxsight Light Delivery Device (Ldd), Rxsight Injector Handpiece, Light Adjustable Lens (Lal) |
| Iridex Corporation | $81.05 | 2019 | |
| Ani Pharmaceuticals, INC. | $55.65 | 2023-2024 | Purified Cortrophin Gel |
| Amgen INC. | $49.55 | 2024-2025 | Tepezza |
| Carl Zeiss Meditec USA, INC. | $43.18 | 2024 | Artevo 800 |
| Shire North American Group INC | $34.77 | 2019 | |
| Mallinckrodt Enterprises LLC | $33.21 | 2019 | |
| Glaukos Corporation | $29.65 | 2024 | Photrexa |
| Astellas Pharma US INC | $29.36 | 2025 | Izervay |
| Coopervision INC. | $24.73 | 2024 | Misight Contact Lens |
| Ocular Therapeutix, INC. | $23.75 | 2023 | Dextenza |
| Thea Pharma INC. | $22.23 | 2022 | |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Omeros Corporation | $15.86 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Davidian listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.